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Abstract
Background: Randomised clinical trials (RCTs) of antiviral interventions in patients with chronic hepatitis C virus
(HCV) infection use sustained virological response (SVR) as the main outcome. There is sparse information on long-
term mortality from RCTs.
Methods: We created a decision tree model based on a Cochrane systematic review on interferon retreatment for
patients who did not respond to initial therapy or who relapsed following SVR. Extrapolating data to 20 years, we
modelled the outcome from three scenarios: (1) observed medium-term (5 year) annual mortality rates continue to
the long term (20 years); (2) long-term annual mortality in retreatment responders falls to that of the general
population while retreatment non-responders continue at the medium-term mortality; (3) long-term annual mortality in
retreatment non-responders is the same as control group non-responders (i.e., the increased treatment-related
medium mortality “wears off”).
Results: The mean differences in life expectancy over 20 years with interferon versus control in the first, second, and
third scenarios were -0.34 years (95% confidence interval (CI) -0.71 to 0.03), -0.23 years (95% CI -0.69 to 0.24), and
-0.01 (95% CI -0.3 to 0.27), respectively. The life expectancy was always lower in the interferon group than in the
control group in scenario 1. In scenario 3, the interferon group had a longer life expectancy than the control group
only when more than 7% in the interferon group achieved SVR.
Conclusions: SVR may be a good prognostic marker but does not seem to be a valid surrogate marker for
assessing HCV treatment efficacy of interferon retreatment. The SVR threshold at which retreatment increases life
expectancy may be different for different drugs depending upon the adverse event profile and treatment efficacy. This
has to be determined for each drug by RCTs and appropriate modelling before SVR can be accepted as a surrogate
marker.
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Introduction
Disease prevalence, mode of transmission, and natural
history of acute and chronic hepatitis C viral infection
Hepatitis C viral (HCV) infection affects 2% to 3% of the
world’s population. This means that about 160 million people
worldwide have chronic HCV infection[1]. HCV is transmitted
by parenteral routes. Risk factors for transmission include
parenteral drug abuse[2], transfusion of infected blood[3],
sexual intercourse with infected individuals[4], perinatal
transmission from mother to child[5], unhygienic tattooing
practices[6], and occupational exposure to the blood of HCV
infected patients[7]. Once infected, approximately 50% to 95%
of patients have persistent HCV RNA in their blood, i.e.,
develop a chronic HCV infection [8–10] depending upon the
genotype of the HCV[9].
The main complication associated with chronic HCV infection
is damage to the liver leading to cirrhosis, decompensated liver
disease, or hepatocellular carcinoma. Chronic hepatitis C is a
slowly progressive disease. Liver-related morbidity and
mortality, if they occur, usually happen 15 to 20 years after
initial infection[11]. Approximately 1% to 39% of patients who
develop chronic HCV infection develop cirrhosis after a period
of 7 to 30 years[11–14]. Every year a proportion of patients
with HCV-related cirrhosis who are referred to hospital with
cirrhosis die (4%), develop liver failure manifested as ascites
(3%), jaundice (2%), gastrointestinal bleeding (1%), or develop
hepatocellular carcinoma (HCC) (4%)[15].
Treatment
Various drugs have been used with the aim of eradicating
chronic HCV infection, thereby preventing all the complications
related to chronic HCV infection and subsequent cirrhosis.
These include interferon (including pegylated interferon),
directly acting anti-viral treatments (ribavirin; protease inhibitors
such as telaprevir, bocerpevir), or a combination of the above
drugs[16]. In patients with significant fibrosis experts currently
recommend a combination of telaprevir or boceprevir,
peginterferon, and ribavirin if the patient has genotype 1 or
pegylated interferon and ribavirin for all other genotypes [16].
How is efficacy of antivirals against hepatitis C
assessed?
The recommendations on treatment for chronic HCV
infection are based on the absence of detectable HCV RNA in
the blood at the end of treatment and at 24 weeks after the end
of treatment (sustained virological response (SVR)). Some
consider SVR as virological ‘cure’ based on the belief that
eradicating the virus from the blood prevents development of
cirrhosis and subsequent complications. Observational studies
have shown that patients who attain SVR have better survival
and lower incidence of HCC than those who do not develop
SVR[17–20]. The US Food and Drug Administration (FDA)
approves drugs used in the treatment of chronic HCV on the
basis of SVR[21]. Thus, SVR is widely believed to be the most
important outcome in assessing the efficacy of treatments for
patients with chronic HCV.
However, achieving SVR may come at the price of exposing
the patients to the adverse events of the drug(s) and it is
necessary to balance the benefits (cure from chronic HCV) and
harms (adverse events and adverse effects; time; costs to
individual and society) of the antiviral intervention. The best
way to assess the benefits and harms of interventions is
through properly conducted systematic reviews of randomised
clinical trials with low risk of systematic errors (bias) and of
random errors (the effect of chance)[22] that assess clinical
and patient-relevant outcomes such as mortality and morbidity
directly.
Evidence from a systematic review of re-treatment of
non-responders and relapsers with interferon
A recent Cochrane systematic review of interferon
retreatment for patients who did not respond to initial interferon
therapy or relapsed after a period of virological response
showed that patients receiving a second course of interferon
alone are 18 times more likely to achieve SVR than those who
received no treatment (3.3% versus 0.2%) [23]. However,
paradoxically there was a 41% (95% confidence limits 2% to
95%) increase in mortality in patients receiving the second
course of interferon as compared with no-intervention controls
after an average follow-up period of 5 to 6 years (9.5% versus
6.7% mortality) based on information from trials with low risk of
bias[23].
Purpose of this study
The contrast between the results of randomised clinical trials
which show no benefit of retreatment with interferon for HCV
despite improvement in SVR and observational studies which
show that patients who obtain SVR fare better is striking. As
randomised clinical trials are considered to be a superior
source of evidence, it appears that interferon is effective in
achieving SVR, yet interferon is associated with a higher
mortality in the medium term (5 to 6 years) when used for
retreatment. The implication is that SVR is not a predictor of
mortality in this group of patients. However, one could argue
that the survival benefit of achieving SVR may only be evident
after further 10 years to 15 years follow-up and that no such
long-term data is available.
While the best way to determine the long-term outcome of
treatment for patients with chronic HCV infection is a
randomised clinical trial with long-term follow-up, there is no
trial that has followed patients for such periods of time. In the
absence of such information, decision modelling provides a
means to incorporate the existing data with other information
(including expert opinion), to determine the likely longer-term
outcomes[24]. Sensitivity analysis can then be used to test the
robustness of the conclusion to model assumptions.
For this study, we employed a simple decision tree model to
combine the medium-term mortality evidence from the
systematic review with various assumptions as to the longer-
term mortality. By making various assumptions as to the long-
term mortality, we determined whether it was possible for SVR
to result in better clinical outcomes over the long term (20
years), despite the poorer medium-term (5 years) outcomes in
patients retreated with interferon monotherapy. Given the
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known medium-term data, if interferon monotherapy results in
superior outcomes only under implausible assumptions for the
longer-term mortality, this analysis would suggest that SVR is
an inappropriate surrogate marker for survival in assessing the
efficacy of a second course of interferon in patients who are
non-responders or relapsers following the initial interferon
intervention.
The findings of this research may be applicable to all non-
responders and relapsers to antiviral therapy, who form more
than 20% of patients with chronic HCV infection with the best
treatments available[16]. In other words, approximately 30
million people may be affected by the results of this analysis.
Methods
Decision tree model
We created a simple decision tree model to illustrate the
possible outcomes for a patient with chronic HCV infection
(Figure 1). The software used was Microsoft Excel 2010.
Patients with chronic HCV with failed first course of antiviral
intervention undergo either intervention or no treatment
(control) (the decision denoted by the blue square). Under
intervention or control, there is a probability of the patient
achieving SVR (denoted by the chance nodes - green circles).
At the terminal nodes (denoted by the red triangles), the
outcome is survival calculated as a simple two state Markov
chain (alive or dead) with transition probabilities equal to the
annual probability of death as described below. The base
patient assumes a 50 year old male relapser or non-responder
over a 20 year time horizon. For purposes of this analysis,
medium-term mortality is the mortality in the first five years and
long-term mortality is from years 5 to 20.
Probabilities
The probabilities of the SVR and the five-year mortality were
obtained from the Cochrane systematic review on ‘Interferon
for interferon non-responding and relapsing patients with
chronic hepatitis C’.[23] In the no-intervention control group,
the SVR was 0.02% and the five-year mortality was 6.72%.
The corresponding SVR and the five-year mortality in the
interferon group were 3.31% and 9.47% based on risk ratios of
14.73 and 1.41 for SVR and five-year mortality,
respectively[23]. Five-year mortality figures were converted to
annual probabilities of death. Probability of SVR with interferon
and mortality with interferon is expressed as the baseline (i.e.,
control) risk multiplied by the risk ratio. Background mortality
for the general population was based on life expectancy tables
for the UK by age [25] (Table 1).
Analysis
The outcome is the expected life years accrued per patient
over a period of 20 years. We divided mortality into two periods
based on the known medium-term mortality and the unknown
long-term mortality. For years 0-4, the mortality from the
Cochrane review was used. Beyond this we explored the
following scenarios, which we considered the worst-case
(scenario 1), the moderate-case (scenario 2), and the best-
case (scenario 3) for use of SVR as a surrogate marker of
mortality.
1. Mortality in both intervention and control groups
continues at the same annual rate for years 5 to 19.
2. Mortality in patients with SVR (achieved on retreatment)
falls to that of the general population for years 5 to 19,
whilst patients with no SVR continue with an annual
mortality risk similar to the rate over the first 5 years. This
is an assumption producing a moderate survival benefit to
SVR patients because some of these patients may have
other risk factors such as intravenous drug abuse and
associated behavioural problems such as chronic
alcoholism which may increase their mortality.
3. Mortality in patients with SVR (achieved on retreatment)
falls to that of the general population for years 5 to 19,
Figure 1.  Decision tree.  This figure shows the possible pathway followed by a patient with chronic hepatitis C infection, who does
not respond to interferon monotherapy.
doi: 10.1371/journal.pone.0083313.g001
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whilst patients with no SVR continue with an annual
mortality risk at the rate for no SVR in the control group.
This is an assumption producing an extreme survival
benefit to SVR patients because the assumption here is
that the harmful effects of the interferon in patients without
SVR have completely worn off while the annual mortality
risk at the rate for SVR is that of the general population.
The death rates in the scenarios are summarised in Table 2.
For each scenario, we have reported the expected life years
accrued by interferon and control patients, the increment,
associated 95% confidence interval, and the probability that
interferon group had longer life expectancy than the control
group. We also calculated the probability that the interferon
group was better than the control group at different hypothetical
SVR proportions in the interferon group. We performed a
threshold analysis for the SVR proportions in the interferon
group to explore whether there is a critical value at which life
years gained in the interferon group was longer than in the
control group. Life years accrued after the first year were
discounted at 3.5% per annum, the currently recommended
rate by UK Government[26].
For the third scenario (long-term mortality in the SVR group
falls to the same as the general population and the long-term
mortality in the no SVR group falls to the same as the short-
term mortality in the control group, i.e., the increased short-
term mortality because of interferon treatment wears off), we
also calculated the probability that the interferon group was
better than control group at different odds ratios of long-term
mortality in the no SVR group compared to the general
population. This was done to account for the possibility of
increased liver-related mortality in patients who did not achieve
SVR which would take up to 20 years to manifest. For the
same scenario, we performed a threshold analysis for the
mortality in the no SVR group to explore whether there was a
critical value of odds ratio at which life years gained in the
interferon group was longer than in the control group. We also
performed a two-way sensitivity analysis to identify the
relationship between the probability of achieving SVR in the
interferon group and the probability of long-term annual
mortality rates in the no SVR group. We also repeated the
analysis in the second scenario in patients of different sex and
ages (50 year old female; 30 year old male; 30 year old female;
70 year old male; 70 year old female).
To take account of uncertainty in mortality and SVR rates,
probability distributions were assigned to all inputs (Table 1)
and a Monte Carlo simulation of 5,000 iterations was
conducted for each analysis.
Table 2. Summary of scenarios.
Scenario:  1 2 3
  
Annual
probability of
mortality
Annual
probability of
mortality
Annual
probability of
mortality
  
Years
0-4 5-19
Years
0-4 5-19
Years
0-4 5-19
Interferon SVR SRi SRi SRi LRp SRi LRp
 NoSVR SRi SRi SRi SRi SRi SRc
Control SVR SRc SRc SRc LRp SRc LRp
 NoSVR SRc SRc SRc SRc SRc SRc
where SVR = sustained virological response, SRi, and SRc = annual risk of death
in interferon and control group as per systematic review; LRp = annual risk of death
in general population (as per notes in Table 1)
doi: 10.1371/journal.pone.0083313.t002
Table 1. Model variables and parameters.
Variable Base case value Distribution   Parameters Source/Notes
Probability of sustained virological
response (SVR) in control group 0.02% Beta Alpha = 1 Beta = 559 Koretz et al.[23]
Log risk ratio (SVR: interferon
versus no-intervention control) 2.9209 Normal
Mean = 2.9209 Standard
deviation = 1.0255
Koretz et al.[23] Note this yields a base case probability of
SVR in the interferon group of 3.31%
5-year probability of death in no-
intervention control group 6.72% Beta Alpha = 57 Beta = 791
Koretz et al.[23] Annual probability therefore = 1.40% (= SRc
in Table 2)
Log risk ratio (death: interferon
versus no-intervention control) 0.3424 (0.1649) Normal
Mean = 0.3424 Standard
deviation = 0.1649
Koretz et al.[23] Note this yields a base case 5 year
probability of death with interferon = 9.47%, annual
probability = 2.01% = SRi in Table 2
Annual all-cause mortality by age
0.34% for 50 year male;
0.23% for 50 year female;
0.09% for 30 year male;
0.04% for 30 year female;
2.17% for 70 year old male;
1.41% for 70 year old female
Constant Not applicable
Interim life tables (based on all reported deaths in the UK)
[25], the sample size is assumed large enough for the
standard error to be zero
Discount rate 3.50% Constant Not applicable HM Treasury Green Book[26]
doi: 10.1371/journal.pone.0083313.t001
Is SVR a Good Marker of HCV Retreatment?
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e83313
Results
The probabilities used in the decision tree are shown in
Table 1.
Life expectancy
The life expectancy was shorter in the interferon group than
the control group in all the scenarios for the base patient
represented by a 50 year old male as shown in Table 3. The
mean difference in life expectancy at 20 years between the
interferon group and the control group in the first scenario was
-0.34 years (95% CI -0.71 to 0.03), in the second scenario was
-0.23 years (95% CI -0.69 to 0.24), and in the third scenario
was -0.21 (95% CI -0.74 to 0.32). The probability that the
interferon group has longer life expectancy than control group
was 1.6% in the first, 11.4% in the second, and 27.9% in the
third scenarios. The probability of interferon resulting in longer
life expectancy than control was always below 2% in the first
scenario irrespective of the proportion of patients who achieved
SVR (Figure 2). As regards to the third scenario, the probability
that interferon results in longer life expectancy than no
intervention increases as the proportion of patients with SVR in
the interferon group increases (Figure 3). For the third
scenario, the probability that interferon results in longer life
expectancy than no intervention increases as the odds ratio of
long-term mortality in the no-SVR group compared with general
population increases, but did not reach beyond 70% even at
odds ratios of 100 (Figure 4).
Threshold analyses
In the first scenario, life expectancy was always lower in the
interferon retreatment group irrespective of the proportion of
patients who achieved SVR, i.e., no threshold level was
reached. As regards to the third scenario, the interferon
retreatment group had longer life expectancy than the control
Figure 2.  Probability that interferon retreatment is better at
different sustained virological response (SVR) proportions
in the interferon group (scenario 1).  The chart shows that
the probability of interferon retreatment resulting in better life
expectancy than no-intervention control group is always below
2% if the long-term mortality in the two groups continued at the
same rates as the short-term mortality (scenario 1).
doi: 10.1371/journal.pone.0083313.g002
Table 3. Results - Life years gained in interferon retreatment versus no-intervention control, increment and 95% confidence
intervals (CI).
Scenario Interferon Control Difference
Probability that interferon results in
longer life expectancy
Scenario 1: 30 years old male 11.75 (95% CI 11.18 to 12.32) 12.1 (95% CI 11.67 to 12.53) -0.35 (95% CI -0.73 to 0.03) 1.30%
Scenario 2: 30 years old male 11.86 (95% CI 11.2 to 12.52) 12.09 (95% CI 11.66 to 12.52) -0.23 (95% CI -0.72 to 0.26) 10.92%
Scenario 3: 30 years old male 12.08 (95% CI 11.56 to 12.61) 12.1 (95% CI 11.66 to 12.54) -0.01 (95% CI -0.32 to 0.29) 27.58%
Scenario 1: 30 years old female 11.58 (95% CI 10.98 to 12.17) 11.93 (95% CI 11.47 to 12.38) -0.35 (95% CI -0.73 to 0.03) 0.98%
Scenario 2: 30 years old female 11.72 (95% CI 11.01 to 12.43) 11.93 (95% CI 11.47 to 12.39) -0.21 (95% CI -0.74 to 0.32) 13.08%
Scenario 3: 30 years old female 11.93 (95% CI 11.38 to 12.49) 11.93 (95% CI 11.48 to 12.38) 0 (95% CI -0.33 to 0.34) 32.08%
Scenario 1: 50 years old male 11.41 (95% CI 10.8 to 12.01) 11.74 (95% CI 11.26 to 12.22) -0.34 (95% CI -0.71 to 0.03) 1.58%
Scenario 2: 50 years old male 11.52 (95% CI 10.86 to 12.18) 11.75 (95% CI 11.27 to 12.23) -0.23 (95% CI -0.69 to 0.24) 11.36%
Scenario 3: 50 years old male 11.74 (95% CI 11.2 to 12.28) 11.75 (95% CI 11.28 to 12.23) -0.01 (95% CI -0.3 to 0.27) 27.86%
Scenario 1: 50 years old female 11.52 (95% CI 10.92 to 12.11) 11.87 (95% CI 11.4 to 12.33) -0.35 (95% CI -0.73 to 0.03) 1.54%
Scenario 2: 50 years old female 11.64 (95% CI 10.98 to 12.3) 11.87 (95% CI 11.41 to 12.32) -0.23 (95% CI -0.7 to 0.25) 11.48%
Scenario 3: 50 years old female 11.85 (95% CI 11.3 to 12.4) 11.86 (95% CI 11.4 to 12.33) -0.01 (95% CI -0.31 to 0.3) 29.50%
Scenario 1: 70 years old male 10.78 (95% CI 10.13 to 11.43) 11.11 (95% CI 10.56 to 11.66) -0.33 (95% CI -0.69 to 0.04) 1.02%
Scenario 2: 70 years old male 10.8 (95% CI 10.17 to 11.43) 11.11 (95% CI 10.56 to 11.65) -0.31 (95% CI -0.65 to 0.03) 0.98%
Scenario 3: 70 years old male 10.99 (95% CI 10.42 to 11.56) 11.11 (95% CI 10.55 to 11.67) -0.12 (95% CI -0.3 to 0.06) 0.98%
Scenario 1: 70 years old female 10.81 (95% CI 10.18 to 11.45) 11.14 (95% CI 10.6 to 11.69) -0.33 (95% CI -0.7 to 0.04) 1.30%
Scenario 2: 70 years old female 10.88 (95% CI 10.27 to 11.49) 11.15 (95% CI 10.61 to 11.69) -0.27 (95% CI -0.6 to 0.06) 3.08%
Scenario 3: 70 years old female 11.06 (95% CI 10.53 to 11.6) 11.14 (95% CI 10.61 to 11.68) -0.08 (95% CI -0.2 to 0.04) 5.38%
Scenario 1, 2, and 3 are shown in table 2.
doi: 10.1371/journal.pone.0083313.t003
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group when the proportion of SVR in the interferon group was
more than 7% (Figure 5). This is an unlikely scenario according
Figure 3.  Probability that interferon retreatment is better at
different sustained virological response (SVR) proportions
in the interferon group (scenario 3).  The chart shows that
the probability of the interferon retreatment group having a
longer life expectancy than the no-intervention control group
increases as the proportion of patients with SVR in the
interferon retreatment group increases. This is only true if the
patients with no SVR in the interferon retreatment group had
long-term mortality at the same rates as the medium-term
mortality in the control group (i.e., the increased mortality in the
medium-term due to interferon retreatment wears off) while
those in the SVR group had a long-term mortality at the same
rate as the general population (scenario 3).
doi: 10.1371/journal.pone.0083313.g003
Figure 4.  Probability that interferon retreatment is better at
different odds ratio of long-term mortality in the no SVR
group compared to the general population (scenario
3).  This chart shows that the probability that interferon
retreatment results in longer life expectancy compared to the
no-intervention control group increases as the odds ratio of
long-term mortality in the no-SVR group increases compared to
the general population.
doi: 10.1371/journal.pone.0083313.g004
to the Cochrane review [23]. For the third scenario, the
interferon retreatment group also had longer life expectancy
than the control group if the odds ratio of long-term mortality in
the no-SVR group was at least 9.00 compared to the general
population (Figure 6). This is an unlikely scenario.
Two-way sensitivity analysis
The two-way sensitivity analysis of the odds ratios of long-
term mortality in the no-SVR group of the interferon retreatment
group compared to the general population versus the
probability of SVR in the interferon retreatment group showed
that in a 50 year old male, the interferon group has longer life
expectancy than the no intervention control group provided that
the long-term mortality in the no SVR group is higher than that
in the general population (Figure 7).
Change in sex and age
The results did not change for different ages and sex (Table
3). The threshold analysis revealed that the threshold of
achieving SVR for the interferon group which resulted in longer
life expectancy than in the control group was lower for a
younger patient compared to an older patient and for a female
compared to a male patient (Table 4), i.e., a lower level of
achieving SVR would be acceptable for the interferon group in
a younger patient compared to an older patient and for a
female compared to a male patient.
Figure 5.  Difference in life expectancy between the
intervention groups at various proportions of sustained
virological response (SVR) in the interferon retreatment
group (scenario 3).  This chart shows that the interferon
retreatment group had a longer life expectancy than the no-
intervention control group if the proportion of patients who
achieved SVR was 0.07 or above in the interferon retreatment
group. This assumes that the patients with no SVR have a
long-term mortality rate comparable to the medium-term
mortality rate in the control group (i.e., the increased mortality
in the medium-term due to treatment wears off) and those in
the SVR group have a long-term mortality rate comparable to
the general population (scenario 3).
doi: 10.1371/journal.pone.0083313.g005
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Figure 6.  Difference in life expectancy between the
intervention groups at different odds ratios of long-term
mortality rates in no sustained virological response (SVR)
group (scenario 3).  This chart shows that the interferon
retreatment group has a longer life expectancy than the no-
intervention control group if the odds ratio of long-term mortality
was 7.00 in the no SVR group compared to the general
population. This also assumes that the patients in the SVR
group had a long-term mortality rate similar to the general
population (scenario 3).
doi: 10.1371/journal.pone.0083313.g006
Figure 7.  Two-way sensitivity analysis.  The two-way
sensitivity analysis of the odds ratios of long-term mortality in
the no-SVR group compared to the general population versus
the probability of SVR in the interferon group showed that in a
50 year old male, the interferon retreatment group had longer
life expectancy than the no-intervention control group provided
that the long-term mortality in the no-SVR group was higher
than the general population.
This assumes that the patients with no SVR have long-term
mortality rate at the same rate as medium-term mortality in
control group (i.e., the increased mortality in the medium-term
due to treatment wears off), and if those in the SVR group had
long-term mortality rates similar to the general population
(scenario 3).
doi: 10.1371/journal.pone.0083313.g007
Discount rate
There was no noticeable change in the results when the
discount rate was altered.
Discussion
Main findings
This study has shown that SVR does not seem to be an
appropriate surrogate outcome in non-responders and
relapsers with chronic HCV infection retreated with interferon
monotherapy. Despite achieving higher rates of viral clearance
from the blood at 24 weeks after finishing retreatment, the
second course of treatment resulted in shorter life expectancy
compared with no treatment. The probability that the interferon
retreatment resulted in improved long-term life expectancy, i.e.,
resulted in survival benefit, compared with the no-intervention
group was less than 32.1% (less than 1 in 3 chance) in any of
the different scenarios that we investigated. Chronic hepatitis C
is a slowly progressive disease and liver-related morbidity and
mortality are likely to occur after 15 to 20 years of having the
disease[11]. However, we assumed that patients with no SVR
had increased mortality in the medium term. This assumption
would tend to favour SVR as a surrogate outcome. Even with
this extreme assumption, the interferon patients who had
higher SVR proportions had shorter life expectancy. Thus, one
cannot consider SVR as a good or valid surrogate outcome for
mortality for this group of patients retreated with interferon
monotherapy. Although the two-way sensitivity analysis
revealed that the interferon group has longer life expectancy
than the no intervention control group, the extreme
assumptions favouring SVR makes this finding unreliable.
Applicability
This study is applicable only in patients with chronic HCV
infection who did not respond to or relapsed following initial
intervention containing interferon. The adverse events related
to a specific treatment may differ to other treatments and hence
the threshold levels at which interferon monotherapy
retreatment becomes beneficial to patients may not be
Table 4. Threshold analysis for sustained virological
response (SVR) proportions in the interferon retreatment
group and long-term mortality rates in the no SVR group.
Age in years   Sex
Proportion of SVR in the
interferon retreatment
group
Odds ratio of mortality in
the no-SVR group
compared to the general
population
30 Male 6% 36.00
30 Female 6% 61.00
50 Male 7% 9.00
50 Female 6% 12.00
70 Male Not reached† 4.00
70 Female Not reached† 4.00
† Probability of SVR was tested between 0 and 1.
doi: 10.1371/journal.pone.0083313.t004
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applicable to other groups of drugs. If SVR is to be used as an
outcome in non-responders or relapsers with different first
courses of treatment, then SVR must be validated as a
surrogate outcome for that drug without assuming
automatically that SVR is a valid surrogate outcome.
As mentioned earlier, in patients with significant fibrosis
experts currently recommend a combination of telaprevir or
boceprevir, peginterferon, and ribavirin if the patient has
genotype 1 or pegylated interferon and ribavirin for all other
genotypes[16]. The proportion of patients who develop SVR is
significantly higher with these drugs[27,28]. Whether the
findings of this research can be extended to treatment naïve
patients, particularly in those receiving telaprevir or boceprevir,
or indeed newer drugs in the near future is not clear, as the
SVR proportions are substantially higher with first treatment
than the SVR observed with interferon retreatment. However,
one has to carefully consider whether SVR is a suitable
surrogate for treatment efficacy in treatment naïve patients and
whether treatments such as telaprevir or boceprevir based on
SVR might actually cause more harm by mechanisms other
than SVR itself, for example, by altering host immunity or by
effects on the replication of non-viral cells. Thus it is important
to validate the use of SVR as a surrogate marker in different
clinical settings and with different therapeutic regimens. The
present study is not applicable to patients with acute HCV
infection or acute or chronic infections of other chronic viral
liver diseases.
Strengths and weaknesses
All-cause mortality compared to liver-related
mortality.  We chose all-cause mortality rather than liver-
related mortality as our patient-relevant outcome. Although
SVR is assumed only to affect liver-related mortality, the risk of
death with and without treatment due to any cause is more
important for the patient. In addition all-cause mortality allows
the success of treatment of chronic HCV to be compared with
that of treatment of other diseases in which liver-related
mortality is not a relevant outcome. This, in turn, allows
appropriate use of limited financial and clinical resources.
Liver-related mortality as an outcome in isolation has little
significance unless all the effects of treatments are completely
understood and there is robust evidence that the treatment
does not have any other adverse effects that may influence
mortality. Furthermore, liver-related mortality is likely to be a
more biased outcome compared to all-cause mortality [22][23].
Sources of information.  While several observational
studies have shown that there is an improvement in survival by
achieving SVR[17,19,20,29], none of the randomised clinical
trials or systematic reviews of such trials have shown that this
is the case[30,31]. This discrepancy could be due to a short
follow-up period in the randomised clinical trials or because of
selection bias in the observational studies. There was clear
selection bias in some observational studies with patients with
co-morbidities not receiving interferon treatment while those
without co-morbidities or concerns related to adverse events of
treatment were given interferon treatment[17,19]. Historical
cohorts were also used[18,20]. Such information is known to be
unreliable and the results are influenced by selection
bias[22,32]. There is no evidence that the information from
such observational studies which include patients with co-
morbidities is better than indirect evidence from randomised
clinical trials in patients without co-morbidities. Ideally,
randomised clinical trials should be performed in patients with
co-morbidities as well so that direct evidence can be obtained.
Our present study is based on information from a systematic
review of randomised clinical trials which provides the best
available evidence[33]. As Cochrane systematic reviews are
generally of a higher standard than other systematic reviews
[34], we obtained the information from a Cochrane review[23].
Where information was not available from systematic reviews
of randomised clinical trials, we made assumptions each time
favouring SVR as a surrogate outcome and performed
sensitivity analyses for a range of values for missing
information. Unless new randomised clinical trials provide
additional information this is currently the best-possible
regarding interferon monotherapy used for retreatment.
Weaknesses of decision tree modelling.  Decision
modelling by definition involves simplification of situations and
making some assumptions. The assumption that the patients
achieving SVR have the same mortality as the general
population is unlikely to be true. This is because these patients
may have other risk factors such as intravenous drug abuse
and associated behavioural problems such as chronic
alcoholism which may increase their mortality compared to the
general population. However, as mentioned previously, despite
our choices of assumptions favouring SVR, the analysis shows
that SVR is not a good and validated surrogate outcome for
mortality. If SVR cannot be validated as a good surrogate
outcome despite this ‘best-case scenario’, one can safely
assume that SVR cannot be a good surrogate outcome in the
real-life scenario or worst-case scenario. So, our conclusions
will not change with plausible changes to these assumptions.
Healthcare decision based on surrogate outcomes
There are costs related to any treatment. There may also be
complications related to the treatment some of which might
involve additional costs to resolve. It is important to maximise
the benefits obtained from finite resources and this involves
decision-making. The use of surrogate outcomes may
decrease the costs and time required for an effective treatment
to reach patients. However, the use of surrogate outcomes is
acceptable only if they have been properly validated[30]. Our
evaluation has shown that, SVR is an unvalidated surrogate
outcome in non-responders or relapsers undergoing interferon
retreatment[30] and thus is not helpful. It is possible, given the
absence of evidence to the contrary, that this may be
applicable with respect to other treatments in this group of
patients considering the criteria for surrogate outcomes[35].
The threshold at which the long-term results of drug treatment
outweigh any short-to medium-term adverse events may be
different for different drugs. Accordingly validation of SVR is
needed for each drug and drug combination, in every clinical
setting, e.g., genotype of HCV, naïve, relapser and null
responder patients, HIV co infected patients, cirrhotic patients
and so on. Drugs which increase SVR may actually cause
more deaths in some settings as evident in the Cochrane
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review[23]. This is not the first time that improvement in a
surrogate outcome has actually resulted in more deaths or
adverse outcomes[30]. Aprotinin decreases massive
perioperative bleeding in patients undergoing high-risk cardiac
surgery, but causes increased mortality when compared with
other anti-fibrinolytics (BART trial)[36]. Aprotinin has now been
withdrawn from the market for this reason[37]. If the BART trial
had not assessed mortality as one of the outcomes it is highly
likely that aprotinin would have been recommended for patients
undergoing high-risk cardiac surgery on the basis of its ability
to decrease massive perioperative bleeding. Risoglitazone
decreases blood glucose and glycosylated haemoglobin but
increases myocardial infarction and mortality in patients with
diabetes[38]. If these outcomes were not measured, it is highly
likely that risoglitazone would be recommended for diabetic
patients based on its ability to decrease blood glucose levels
and glycosylated haemoglobin. It is clear from the above
examples that the use of unvalidated surrogate outcomes to
justify use of therapy requires extreme caution. However, SVR
has been accepted as a surrogate outcome by the medical and
pharmaceutical community as well as the regulatory authorities
without proper validation in every setting in which antiviral
therapy is used.
Can SVR be used as a surrogate outcome for mortality
and what are the implications?
There is no high-quality evidence to suggest that the long-
term quality of life is better in patients who achieved SVR after
retreatment. In the absence of such evidence of improvement
in quality of life to compensate for the decreased life
expectancy for retreatment, it is mandatory to inform such
patients that a higher medium-term risk of death due to
retreatment exists and that data for other treatments are not
available. There is no scientific proof that interferon versus no
intervention affects clinical outcomes positively[39]; that
interferon plus ribavirin versus interferon affects clinical
outcomes positively[31]; and that the newer antivirals combined
with interferon plus ribavirin versus interferon plus ribavirin
affects clinical outcomes positively[40]. HCV-related liver
complications can occur even in patients who have achieved
SVR and in addition, factors such as younger age, female sex,
and low or no alcohol intake are common predictors of SVR
and benign course of chronic HCV in untreated
individuals[41–43]. Thus, SVR may not have a strong
relationship with the decrease in liver-related complications at
least in retreated patients with chronic HCV.
A recent article criticised the use of glycosylated
haemoglobin as a surrogate outcome for the assessment of
efficacy of hypoglycaemic agents in diabetic patients[44].
Experts in evidence-based medicine do not recommend that
surrogate outcomes be included in lists of outcomes except for
exploration of mechanisms[32], although not withstanding this,
SVR is the primary outcome in all therapeutic trial of antiviral
therapy for HCV. Clinicians, researchers, drug companies and
regulatory authorities should validate SVR as a surrogate
outcome before using it as a primary outcome. An association
of SVR with decreased mortality in observational studies is not
enough to promote or prescribe a treatment because of the
presence of confounding factors, which may themselves be
causally related to the outcomes. Only a moderate proportion
of patients with chronic HCV infection develop liver cirrhosis.
The outcome in the entire group of treated patients is more
important rather than the outcome in patients who have
achieved SVR. While retreatment with interferon monotherapy
may be applicable to only a small proportion of patients in the
future, the principles of our present analyses are relevant for all
interventions related to the treatment of patients with chronic
HCV in the various clinical settings.
Costs and cost-effectiveness of treatments
Throughout this discussion, we have not discussed the cost
of the drug treatment. In the setting of state-funded healthcare
systems, additional information regarding cost of the drug
treatment and the quality of life of patients in the long-term are
taken into account in determining whether treatment can be
recommended. Such cost-effective analyses are likely to give
wrong results (and hence wrong recommendations) if only
unvalidated SVR is used in the modelling. Long term outcomes
need to be evaluated.
Conclusions
SVR is neither a good nor a validated surrogate marker for
mortality in non-responders and relapsers with chronic HCV
infection undergoing interferon reintervention after failed first
course of interferon intervention. This observation may be
different for different drugs and clinical settings. Validation of
SVR should be performed for each individual drug and drug
combination in each different clinical setting. Drug licensing
agencies and national and international bodies should review
the evidence that SVR is a suitable outcome for drugs used for
re-treating such patients. Long-term outcomes of patients with
chronic HCV infection involved in trials comparing treatments
aimed at improving SVR need to be obtained and
systematically re-evaluated to determine whether SVR is a
valid surrogate outcome and the level of SVR at which the drug
becomes beneficial to the patient.
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